QNCX Quince Therapeutics
Quince Therapeutics earnings company data as of 4:47 AM ET 10/12
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 11 Nov | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 14 Aug | EPS | — | -12.31 | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by QNCX's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $174K sold by 1 insider outside a trading plan
- None no planned (10b5-1) sales
-
Luca Benatti DirectorSale$174K 50,000 shares at $3.47 56% of stakeTraded Dec 26, 2025 Filed Dec 29, 2025
Also filed in the last 12 months, not counted as buying or selling: 2 gifts and 2 option exercises.
SEC filings
Recent issuer filings from EDGAR, 25 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 7.01,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 5.02,5.03,7.01,8.01,9.01 | Filing Doc | |
| 8-K | 5.02,5.03,5.07,9.01 | Filing Doc | |
| DEFA14A | Filing Doc | ||
| 8-K | 5.02 | Filing Doc | |
| 8-K | 2.01,5.02,9.01 | Filing Doc | |
| 8-K | 3.01 | Filing Doc | |
| 8-K | 5.02 | Filing Doc | |
| DEF 14A | Filing Doc | ||
| 8-K | 8.01,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 5.02 | Filing Doc | |
| 8-K/A | 8.01,9.01 | Filing Doc | |
| 8-K | 3.03,5.03,9.01 | Filing Doc | |
| 8-K/A | 3.03 | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.